Search
Close this search box.

HIV Management Guide for Clinical Care

HIV Management Guide for Clinical Care

Search
Close this search box.

ARV Drugs & other Therapies

Management > ARV Drugs & other Therapies > References

Sections

Sections

References

  1. Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive Haemophilus influenzae infections in men with HIV infection. Jama. 1992 Dec 16;268(23):3350-2. PubMed PMID: 1453528. Epub 1992/12/16. eng.
  2. von Gottberg A, de Gouveia L, Madhi SA, du Plessis M, Quan V, Soma K, et al. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bulletin of the World Health Organization. 2006 Oct;84(10):811-8. PubMed PMID: 17128361. Pubmed Central PMCID: PMC2627490. Epub 2006/11/28. eng.
  3. Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002 Feb 1;34(3):379-85. PubMed PMID: 11774086. Epub 2002/01/05. eng.
  4. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS (London, England). 2005 Oct 14;19(15):1702-4. PubMed PMID: 16184045. Epub 2005/09/27. eng.
  5. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. Journal of viral hepatitis. 2007 Mar;14(3):189-93. PubMed PMID: 17305885. Epub 2007/02/20. eng.
  6. Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology (Baltimore, Md). 2013 May;57(5):1734-41. PubMed PMID: 23258666. Epub 2012/12/22. eng.
  7. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. Jama. 2011 Apr 13;305(14):1432-40. PubMed PMID: 21486976. Epub 2011/04/14. eng.
  8. Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boelle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Apr;58(8):1130-9. PubMed PMID: 24415637. Pubmed Central PMCID: PMC4761378. Epub 2014/01/15. eng.
  9. Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World journal of gastroenterology. 2014 Oct 28;20(40):14598-614. PubMed PMID: 25356024. Pubmed Central PMCID: PMC4209527. Epub 2014/10/31. eng.
  10. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005 Apr 22;23(22):2902-8. PubMed PMID: 15780739. Epub 2005/03/23. eng.
  11. Biggar R, Goedert J, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficiency homosexual men infected with HIV. New England Journal of Medicine. 1987;316(10):630-21.
  12. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Annals of internal medicine. 1988 Jul 15;109(2):101-5. PubMed PMID: 2968064. Epub 1988/07/15. eng.
  13. Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? International journal of STD & AIDS. 2013 Feb;24(2):117-22. PubMed PMID: 23467291. Epub 2013/03/08. eng.
  14. Potsch DV, Oliveira ML, Ginuino C, Miguel JC, Oliveira SA, Silva EF, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010 Feb 10;28(6):1447-50. PubMed PMID: 19995540. Epub 2009/12/10. eng.
  15. Wakeham K, Kavanagh K. The burden of HPV-associated anogenital cancers. Current oncology reports. 2014 Sep;16(9):402. PubMed PMID: 25118645. Epub 2014/08/15. eng.
  16. Poynten IM, Jin F, Templeton DJ, Prestage GP, Donovan B, Pawlita M, et al. Prevalence, incidence, and risk factors for human papillomavirus 16 seropositivity in Australian homosexual men. Sexually transmitted diseases. 2012 Sep;39(9):726-32. PubMed PMID: 22902671. Epub 2012/08/21. eng.
  17. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (London, England). 2007 Jul 7;370(9581):59-67. PubMed PMID: 17617273. Epub 2007/07/10. eng.
  18. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. The Lancet Oncology. 2012 May;13(5):487-500. PubMed PMID: 22445259. Epub 2012/03/27. eng.
  19. Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA, 3rd, et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. The Journal of infectious diseases. 2012 Oct;206(8):1309-18. PubMed PMID: 22859825. Pubmed Central PMCID: PMC3529604. Epub 2012/08/04. eng.
  20. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Jul 1;59(1):127-35. PubMed PMID: 24723284. Pubmed Central PMCID: PMC4305143. Epub 2014/04/12. eng.
  21. Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the Immunogenicity and Reactogenicity of Cervarix(R) and Gardasil(R) Human Papillomavirus Vaccines in HIV-infected Adults: A Randomized, Double-Blind, Clinical Trial2013.
  22. Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Oct;55(7):996-1003. PubMed PMID: 22715173. Pubmed Central PMCID: PMC3657519. Epub 2012/06/21. eng.
  23. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011. Emerging infectious diseases. 2013 Nov;19(11):1766-74. PubMed PMID: 24209781. Pubmed Central PMCID: PMC3837669. Epub 2013/11/12. eng.
  24. Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Jan 15;52(2):219-27. PubMed PMID: 21288848. Pubmed Central PMCID: PMC4990828. Epub 2011/02/04. eng.
  25. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. The New England journal of medicine. 2014 Aug 14;371(7):635-45. PubMed PMID: 25119609. Epub 2014/08/15. eng.
  26. Kaka AS, Filice GA, Myllenbeck S, Nichol KL. Comparison of Side Effects of the 2015-2016 High-Dose, Inactivated, Trivalent Influenza Vaccine and Standard Dose, Inactivated, Trivalent Influenza Vaccine in Adults >/=65 Years. Open forum infectious diseases. 2017 Winter;4(1):ofx001. PubMed PMID: 28480274. Pubmed Central PMCID: PMC5414012. Epub 2017/05/10. eng.
  27. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS (London, England). 2010 Sep 10;24(14):2187-92. PubMed PMID: 20616698. Epub 2010/07/10. eng.
  28. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Jan 1;52(1):138-46. PubMed PMID: 21148532. Pubmed Central PMCID: PMC3060889. Epub 2010/12/15. eng.
  29. Yamanaka H, Teruya K, Tanaka M, Kikuchi Y, Takahashi T, Kimura S, et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. Journal of acquired immune deficiency syndromes (1999). 2005 Jun 1;39(2):167-73. PubMed PMID: 15905732. Epub 2005/05/21. eng.
  30. Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PloS one. 2011 Mar 25;6(3):e17758. PubMed PMID: 21512577. Pubmed Central PMCID: PMC3064575. Epub 2011/04/23. eng.
  31. Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine. 2014 Sep 29;32(43):5585-92. PubMed PMID: 25131742. Epub 2014/08/19. eng.
  32. Moss WJ, Fisher C, Scott S, Monze M, Ryon JJ, Quinn TC, et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Feb 15;46(4):523-7. PubMed PMID: 18194095. Epub 2008/01/16. eng.
  33. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. The Cochrane database of systematic reviews. 2012 Feb 15(2):CD004407. PubMed PMID: 22336803. Pubmed Central PMCID: PMC6458016. Epub 2012/02/18. eng.
  34. Belaunzaran-Zamudio PF, Garcia-Leon ML, Wong-Chew RM, Villasis-Keever A, Cuellar-Rodriguez J, Mosqueda-Gomez JL, et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine. 2009 Nov 23;27(50):7059-64. PubMed PMID: 19799846. Epub 2009/10/06. eng.
  35. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Apr 1;32(7):1090-4. PubMed PMID: 11264038. Epub 2001/03/27. eng.
  36. MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons – Advisory Committee on Immunization Practices, 2016. MMWR Morbidity and mortality weekly report. 2016 Nov 4;65(43):1189-94. PubMed PMID: 27811836. Epub 2016/11/05. eng.
  37. Siberry GK, Williams PL, Lujan-Zilbermann J, Warshaw MG, Spector SA, Decker MD, et al. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. The Pediatric infectious disease journal. 2010 May;29(5):391-6. PubMed PMID: 20431379. Pubmed Central PMCID: PMC2868314. Epub 2010/05/01. eng.
  38. Frota AC, Milagres LG, Harrison LH, Ferreira B, Menna Barreto D, Pereira GS, et al. Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil. The Pediatric infectious disease journal. 2015 May;34(5):e113-8. PubMed PMID: 25876102. Pubmed Central PMCID: PMC4454630. Epub 2015/04/16. eng.
  39. Bliss SJ, O’Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. The Lancet Infectious diseases. 2008 Jan;8(1):67-80. PubMed PMID: 17974480. Epub 2007/11/03. eng.
  40. Marcus JL, Baxter R, Leyden WA, Muthulingam D, Yee A, Horberg MA, et al. Invasive Pneumococcal Disease Among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System. AIDS patient care and STDs. 2016 Oct;30(10):463-70. PubMed PMID: 27749111. Pubmed Central PMCID: PMC6445197. Epub 2016/10/18. eng.
  41. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Moore DP, Klugman KP, et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS (London, England). 2011 Feb 20;25(4):453-62. PubMed PMID: 21178754. Epub 2010/12/24. eng.
  42. Pesola GR, Charles A. Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome. Chest. 1992 Jan;101(1):150-5. PubMed PMID: 1729061. Epub 1992/01/01. eng.
  43. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal Disease among Human Immunodeficiency Virus-Infected Persons: Incidence, Risk Factors, and Impact of Vaccination. Clinical Infectious Diseases. 2001;32(5):794-800.
  44. French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. The New England journal of medicine. 2010 Mar 4;362(9):812-22. PubMed PMID: 20200385. Pubmed Central PMCID: PMC2873559. Epub 2010/03/05. eng.
  45. Bhorat AE, Madhi SA, Laudat F, Sundaraiyer V, Gurtman A, Jansen KU, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS (London, England). 2015 Jul 17;29(11):1345-54. PubMed PMID: 25888646. Pubmed Central PMCID: PMC4521829. Epub 2015/04/19. eng.
  46. Glesby MJ, Watson W, Brinson C, Greenberg RN, Lalezari JP, Skiest D, et al. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. The Journal of infectious diseases. 2015 Jul 1;212(1):18-27. PubMed PMID: 25395187. Epub 2014/11/15. eng.
  47. Rodriguez-Barradas MC, Musher DM, Lahart C, Lacke C, Groover J, Watson D, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. The Journal of infectious diseases. 1992 Mar;165(3):553-6. PubMed PMID: 1347058. Epub 1992/03/01. eng.
  48. Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998–2003. Vaccine. 2008 Oct 29;26(46):5830-4. PubMed PMID: 18786586. Epub 2008/09/13. eng.
  49. Molton J, Smith C, Chaytor S, Maple P, Brown K, Johnson M, et al. Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults. The Journal of infection. 2010 Jul;61(1):73-80. PubMed PMID: 20403382. Epub 2010/04/21. eng.
  50. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. Journal of acquired immune deficiency syndromes (1999). 2012 Oct 1;61(2):203-7. PubMed PMID: 22766968. Pubmed Central PMCID: PMC4154488. Epub 2012/07/07. eng.
  51. Armenian SH, Han JY, Dunaway TM, Church JA. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. The Pediatric infectious disease journal. 2006 Apr;25(4):368-70. PubMed PMID: 16567993. Epub 2006/03/29. eng.
  52. Benson CA, Andersen JW, Macatangay BJC, Mailliard RB, Rinaldo CR, Jr., Read S, et al. Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Nov 13;67(11):1712-9. PubMed PMID: 29590326. Pubmed Central PMCID: PMC6233680. Epub 2018/03/29. eng.
  53. Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. The Journal of infectious diseases. 2015 Apr 15;211(8):1279-87. PubMed PMID: 25371534. Pubmed Central PMCID: PMC4371767. Epub 2014/11/06. eng.
  54. Gibb DM, Duong T, Tookey PA, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ (Clinical research ed). 2003 Nov 1;327(7422):1019. PubMed PMID: 14593035. Pubmed Central PMCID: PMC261655. Epub 2003/11/01. eng.
  55. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S, Gonzalez Tomee MI, Rojo Conejo P, Ferrnado Vivas P, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. The Pediatric infectious disease journal. 2003 Oct;22(10):863-7. PubMed PMID: 14551485. Epub 2003/10/11. eng.
  56. Menson EN, Mellado MJ, Bamford A, Castelli G, Duiculescu D, Marczynska M, et al. Guidance on vaccination of HIV-infected children in Europe. HIV medicine. 2012 Jul;13(6):333-6; e1-14. PubMed PMID: 22296225. Epub 2012/02/03. eng.
  57. Children’s HIV Association. Vaccination of HIV infected children. United Kingdom2018.
  58. Hesseling AC, Cotton MF, Fordham von Reyn C, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. International Journal of Tuberculosis and Lung Disease. 2008;12:1376-79.
  59. Mansoory N, Scriba TJ, Kock M, et al. HIV-1 infection in infants severely impairs the immuno response induced by Bacille Calmette-Guein vaccine. Journal of Infectious Diseases. 2009;199:982-90.
  60. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practicer (ACIP). Centres for Disease Control and Prevention, 1996.
  61. Cunliffe NA, Gondwe JS, Kirkwood CD, Graham SM, Nhlane NM, Thindwa BD, et al. Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian children. Lancet (London, England). 2001 Aug 18;358(9281):550-5. PubMed PMID: 11520526. Epub 2001/08/25. eng.
  62. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. New England Journal of Medicine. 2010;362(4):289-98. PubMed PMID: 20107214.
  63. Steele AD, Cunliffe N, Tumbo J, Madhi SA, De Vos B, Bouckenooghe A. A Review of Rotavirus Infection in and Vaccination of Human Immunodeficiency Virus–Infected Children. The Journal of infectious diseases. 2009;200(Supplement_1):S57-S62.
  64. Steele AD, Madhi SA, Louw CE, Bos P, Tumbo JM, Werner CM, et al. Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South Africa. The Pediatric infectious disease journal. 2011 Feb;30(2):125-30. PubMed PMID: 20842070. Epub 2010/09/16. eng.
  65. N Serpe J, Schmitz V, Lepage P. Vaccinations in HIV-infected children2006. 923-30 p.
  66. Li-Kim Moy J, Yin JK, Blyth CC, Et al. Influenza hospitalizations in Australian children. Epidemiology and Infection. 2017;145:1451-60.
  67. Li-Kim Moy J, Yin JK, Patel C, et al. Australian vaccine preventable disease edpidemiologyical review series: influenza 2006-2015. Communicable Diseases Intelligence. 2016;40:482-95.
  68. Klugman KP, Dagan R, Malley R, Whitney CG. Pneumonoccal conjugate vaccine and pneumococcal common protein vaccine. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines. 7th ed ed. Philadelphia: Elsevier; 2018.
  69. Weinberger DM, Harboe ZB, Sanders ED, al. e. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clinical infectious diseases. 2010;51:pp692-9.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top